Writing for Wellbeing Magazine, Scott Mazza, co-founder of Vitality CBD, examines what the current research does and does not establish about CBD as a non-intoxicating option for neuropathy and chronic nerve pain. Mazza reviews emerging clinical and peer-reviewed studies in which CBD was associated with reductions in pain intensity, improvements in sleep quality, and greater mobility, effects researchers attribute to activity at the endocannabinoid system, while noting that the evidence base is still early. He argues that product quality determines whether any of that research is relevant to what a consumer actually buys, making the case for organic cultivation, safe extraction, and third-party testing as the baseline for topicals and salves in this category.

In this Wellbeing Magazine article, Scott Mazza, co-founder of Vitality CBD and Certified Headies, explains why CBD salves and topicals have emerged as one of the most durable, science-aligned applications of cannabidiol as novelty products fade. Drawing on existing research and consumer use patterns, Mazza describes how non-ingestible CBD is understood to act locally at the endocannabinoid system, and reviews the research examining topical application in relation to pain, inflammation, muscle tension, and sleep routines. He also stresses the importance of product quality, third-party testing, and clean formulations, noting that regulatory gaps make consumer diligence essential when applying CBD directly to the skin.

In this Wellbeing Magazine article, Scott Mazza, co-founder of Vitality CBD and Certified Headies, explains how THCA differs from THC, why it is non-intoxicating in its raw form, and how heat-driven conversion creates both its psychoactive potential and legal complexity. Mazza details how THCA remains legal in the U.S. under the 2018 Farm Bill and in the U.K. due to its exclusion from controlled substance listings, while noting that proposed “total THC” standards could significantly alter its status. He emphasizes the need for clear, science-based regulation and consumer diligence, highlighting the importance of third-party testing and quality standards in an underregulated market.

In this Wellbeing Magazine article, Scott Mazza, Co-Founder of Vitality CBD and Certified Headies, explains what THCA is, how it differs from THC, and why it has emerged as a legally distinct hemp-derived cannabinoid under the 2018 Farm Bill. Mazza outlines early scientific research suggesting potential anti-inflammatory, neuroprotective, and anti-nausea properties, while emphasizing that findings remain preliminary. He also examines the evolving regulatory landscape, warning that proposed changes to federal hemp law could significantly impact THCA’s legality and arguing for clear, science-based regulation rather than blanket product bans.

In this wellness-focused feature, Scott Mazza, co-founder and COO of Vitality CBD, reviews emerging research on CBD’s effects on exercise performance, anxiety, and perceived exertion. Drawing on peer-reviewed studies, the article explains how CBD may reduce exercise-related anxiety and improve subjective workout experiences without impairing performance, while also examining its potential role in recovery, inflammation, and sleep. Mazza emphasizes cautious adoption, product quality, and third-party testing as athletes and professional sports organizations increasingly evaluate cannabis compounds within training and wellness routines.

In this analysis, Scott Mazza of Vitality CBD reviews recent peer-reviewed studies examining cannabidiol in the context of opioid dependence, including research on opioid reward, pain, and CBD’s interaction with naloxone. He emphasizes that these findings are early, and that widespread mislabeling, contamination, and the absence of regulatory oversight mean nothing in this literature translates into safe clinical use today. The article argues that FDA guidance, medical-grade production standards, and routine third-party testing are the preconditions for CBD to be studied credibly as part of the response to the opioid crisis.

In this evidence-focused commentary, Scott Mazza of Vitality CBD examines what current research does (and does not) support regarding CBD’s role in women’s health. He reviews early findings on menopause-related symptoms, anxiety, and inflammation while cautioning that the largely unregulated CBD market has enabled misleading claims and inconsistent product quality. The article emphasizes responsible use, third-party testing, and the need for continued clinical research as the sector matures toward more credible, science-led outcomes.